ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,901 to 1,920 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Treatment Group vs Control Group: Self-reported Lifetime Inhalant Use379 of 2,324

342 of 2,358

1.8 points

-0.3 to 3.9

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported 30-day Inhalant Use239 of 2,324

224 of 2,358

0.8 points

-0.9 to 2.5

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported Lifetime Alcohol Use1,288 of 2,324

1,236 of 2,358

3.0 points

0.1 to 5.9

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported 30-day Use of Alcohol332 of 2,324

330 of 2,358

0.3 points

-1.7 to 2.3

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported Lifetime Marijuana Use265 of 2,324

238 of 2,358

1.3 points

-0.5 to 3.1

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported 30-day Use of Cigarettes144 of 2,324

130 of 2,358

0.7 points

-0.7 to 2.0

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported 30-day Marijuana Use116 of 2,324

130 of 2,358

-0.5 points

-1.8 to 0.8

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Treatment Group vs Control Group: Self-reported Lifetime Cigarette Use544 of 2,324

439 of 2,358

4.8 points

2.5 to 7.1

4,682NCT00650585

An Effectiveness Trial of Project ALERT

Colchicine vs Colchicine Placebo: deaths from any cause41 of 2,330

44 of 2,346

-0.1 points

-0.9 to 0.7

4,676NCT02551094

Colchicine Cardiovascular Outcomes Trial (COLCOT)

Colchicine vs Colchicine Placebo: serious adverse events383 of 2,330

404 of 2,346

-0.8 points

-2.9 to 1.4

4,676NCT02551094

Colchicine Cardiovascular Outcomes Trial (COLCOT)

Interactive Two-way SMS Dialogue vs No SMS Control: Thermal Care2,245 of 2,332

2,232 of 2,343

1.0 points

-0.2 to 2.2

4,675NCT04598165

Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support

SMC021 vs Placebo: Number of Patients With Non-vertebral Fractures75 of 2,334

82 of 2,331

-0.3 points

-1.4 to 0.7

4,665NCT00525798

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

SMC021 vs Placebo: serious adverse events340 of 2,334

378 of 2,331

-1.6 points

-3.7 to 0.4

4,665NCT00525798

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

Exemestane vs Tamoxifen: serious adverse events383 of 2,320

439 of 2,338

-2.3 points

-4.5 to -0.1

4,658NCT00038467

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Survive at Day 28 vs Non-survive at Day 28: serious adverse events1,070 of 4,010

519 of 642

-54.2 points

-57.3 to -50.6

4,652NCT01354197

The Thai Surgical Intensive Care Study (Thai-SICU Study)

FluBlok (Lots A, B, C) vs Placebo: Number of Participants Reporting Unsolicited Adverse Events61 of 2,344

67 of 2,304

-0.3 points

-1.3 to 0.6

4,648NCT00539981

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

FluBlok (Lots A, B, C) vs Placebo: deaths from any cause1 of 2,344

1 of 2,304

-0.0 points

-0.2 to 0.2

4,648NCT00539981

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

FluBlok (Lots A, B, C) vs Placebo: serious adverse events30 of 2,344

34 of 2,304

-0.2 points

-0.9 to 0.5

4,648NCT00539981

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Dronedarone 400mg Bid vs Placebo: Cardiovascular Death65 of 2,301

94 of 2,327

-1.2 points

-2.3 to -0.2

4,628NCT00174785

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Dronedarone 400mg Bid vs Placebo: First Hospitalization for Cardiovascular Reason or Death From Any Cause734 of 2,301

917 of 2,327

-7.5 points

-10.2 to -4.8

4,628NCT00174785

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=96"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=96

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00650585-01ee93ef",
        "title": "Treatment Group vs Control Group: Self-reported Lifetime Inhalant Use",
        "summary": "379 of 2324 against 342 of 2358; risk difference 1.8 points, 95% interval -0.3 to 3.9; NCT00650585, An Effectiveness Trial of Project ALERT",
        "record": "/library/comparisons/NCT00650585-01ee93ef",
        "nct_id": "NCT00650585",
        "kind": "outcome",
        "participants": 4682,
        "risk_difference": {
          "value": 0.018042727069674552,
          "lower": -0.002643350176353601,
          "upper": 0.03874272744341799
        },
        "group_1": "379 of 2,324",
        "group_2": "342 of 2,358",
        "difference": "1.8 points",
        "interval": "-0.3 to 3.9",
        "trial_title": "An Effectiveness Trial of Project ALERT"
      },
      {
        "id": "NCT00650585-067c3337",
        "title": "Treatment Group vs Control Group: Self-reported 30-day Inhalant Use",
        "summary": "239 of 2324 against 224 of 2358; risk difference 0.8 points, 95% interval -0.9 to 2.5; NCT00650585, An Effectiveness Trial of Project ALERT",
        "record": "/library/comparisons/NCT00650585-067c3337",
        "nct_id": "NCT00650585",
        "kind": "outcome",
        "participants": 4682,
        "risk_difference": {
          "value": 0.007844172035287644,
          "lower": -0.009279461854693999,
          "upper": 0.025002466147200766
        },
        "group_1": "239 of 2,324",
        "group_2": "224 of 2,358",
        "difference": "0.8 points",
        "interval": "-0.9 to 2.5",
        "trial_title": "An Effectiveness Trial of Project ALERT"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=97",
  "request_id": "r_zAi4Jx45GUERV-"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?